September 12th, 2018
Applications are due September 21 for funded travel to and attendance at the mobilize workshop, Rapid Biomedical Knowledge Base Construction from Text, at Stanford University. The November workshop is free to attend, but space is limited.
Don’t Miss the 2019 Science of Team Science (SciTS) Conference May 20-23, 2019 in Lansing, Michigan!September 12th, 2018
The Science of Team Science conference is the annual international forum dedicated to bringing together thought leaders and practitioners from a broad range of disciplines, fields, and professions. Click the title above to learn more, including the abstract submission and registration deadlines.
September 10th, 2018Experts from FDA’s Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), the University of Maryland, and the University of Pennsylvania will provide a deep dive into the scientific background and practical methodology needed when conducting clinical trials.
September 4th, 2018The purpose of this contest is to find the best ideas in all of CTSA-land for encouraging better team science. Any person associated with a CTSA hub is eligible. Click the title above to learn more.
June 7th, 2018
Translating Translation "NCATS is unique at NIH in that the name in the Center’s mission — “translation” — has a firmly established meaning that is generally associated with languages, not biomedical research. By contrast, other NIH components are named for widely known medical problems, such as cancer, diabetes and stroke."
June 4th, 2018
"The modern news release is now directly consumed by the public. Here are some of the best practices gathered by NIH communications offices for writing clear news releases that also inform the public about a scientific finding."
June 4th, 2018
In late April, Dr. Mike Lauer, NIH Deputy Director for Extramural Reserach, wrote about the benefits and drawbacks of using surrogate endpoints in clinical trials. Read his thoughts here...
May 23rd, 2018
May 28th, 2018 is the final day to submit Letters of Intent and CVs for the NIH Lasker Clinical Research Scholars Program. All submissions must be forwarded to the attention of CTSI-CN KL2 Program Lead, Ms. Rachel Smilow at firstname.lastname@example.org.
May 21st, 2018
Thinking about becoming an Early Career Reviewer (ECR)? By joining the National Institutes of Health Center for Scientific Review's Early Career Reviewer Program you can learn from the experiences of ECRs who have served on NIH Peer Review study sections.
May 2nd, 2018
George Washington University is offering a new online, 3-credit-hour, 30-CME course, Grantsmanship in Clinical and
March 19th, 2018
Join the National Research Mentoring Network (NRMN) for the 2018 MyMentor mystery series titled "The Puzzle of Missing
Information." Taking place the last Thursday of each month from March to July, this webinar series will cover a wide range
of topics and will provide hot tips for both novice and experienced researchers.
February 16th, 2018
The CTSI-CN announces the 2018-2019 Request for Applications (RFA) for the Mentored Career Development Award (KL2).
Please review the RFA in detail to learn more about this funding opportunity.
February 2nd, 2018
Patients Are Key to Rare Disease Day at NIH There are about 7,000 diseases officially defined as “rare,” or affecting
fewer than 200,000 people in the U.S.; only a few hundred of these diseases have any approved treatment.
February 2nd, 2018Learn more about NIH Research Highlights in 2017 here.
February 1st, 2018Check Out the Latest Issue of Peer Review Notes: www.csr.nih.gov/prn
1. Assuring the Integrity of Peer Review
2. Heads Up on New and Emerging Policies
3. What Happened When NSF Had Applicants Do Reviews? ...
January 27th, 2018
Innovations to Increase Participation in Clinical Research Every person with an illness wants the best treatment
available, and given the pace of biomedical research, that best treatment may be new or even still under study. It is
curious, therefore, that only a small number of people with any disease — generally less than 10 percent — participate
in clinical trials of new treatments.